Skip to content

Bioalmanac

ARA-290

Cibinetide · Erythropoietin helix B surface peptide · pHBSP

Clinical trials

Status reviewed 16 Aug 2026

An eleven-amino-acid fragment of erythropoietin that keeps the tissue-repair signalling and drops the blood-thickening. Studied properly in nerve damage, with a published randomised trial.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 5 mg vial, 4000 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL5 mg/mL0.8 mL80 units1.3
2 mL2.5 mg/mLExceeds a 1 mL barrel
3 mL1.667 mg/mLExceeds a 1 mL barrel
5 mL1 mg/mLExceeds a 1 mL barrel

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Phase 2 protocol for small fibre neuropathy4000 mcgOnce daily for 28 daysClinical trial
Commonly described community protocol1000–4000 mcgOnce daily in courses of several weeksCommunity practice

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • An injection site that becomes hot, spreading or produces pus.
  • Worsening neuropathic pain rather than improvement.
  • Persistent headache that does not settle.

Not approved for any indication. Has completed randomised phase 2 trials in neuropathy and holds orphan drug designation for sarcoidosis in both the United States and the European Union. Material sold as a research chemical is not the clinical product.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/ara-290

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.